ArticleBiosensors2025
A Microfluidic Device Integrating a Glucose Sensor and Calibration Function for Cell-Based Assays.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Microphysiological systems (MPS) incorporating microfluidic technologies offer improved physiological relevance and real-time analysis for cell-based assays, but often lack non-invasive monitoring capabilities. Addressing this gap, we developed a microfluidic cell-based assay platform integrating an electrochemical biosensor for real-time, non-invasive monitoring of kinetic cell status through glucose consumption. The platform addresses the critical limitations of traditional cell assays, which typically rely on invasive, discontinuous methods. By combining enzyme-modified platinum electrodes within a microfluidic device, our biosensor can quantify dynamic changes in glucose concentration resulting from cellular metabolism. We have integrated a calibration function that corrects sensor drift, ensuring accurate and prolonged short-term measurement stability. In the validation experiments, the system successfully monitored glucose levels continuously for 20 h, demonstrating robust sensor performance and reliable glucose concentration predictions. Furthermore, in the cell toxicity assays using HepG2 cells exposed to varying concentrations of paraquat, the platform detected changes in glucose consumption, effectively quantifying the cellular toxicity responses. This capability highlights the device's potential for accurately assessing the dynamic physiological conditions of the cells. Overall, our integrated platform significantly enhances cell-based assays by enabling continuous, quantitative, and non-destructive analysis, positioning it as a valuable tool for future drug development and biomedical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.